British Statewide Parties and Multilevel Politics
In: Publius: the journal of federalism, Band 36, Heft 1, S. 135-152
ISSN: 1747-7107
5 Ergebnisse
Sortierung:
In: Publius: the journal of federalism, Band 36, Heft 1, S. 135-152
ISSN: 1747-7107
In: Politics & society, Band 44, Heft 3, S. 335-343
ISSN: 0032-3292
In: European journal of political research: official journal of the European Consortium for Political Research, Band 35, Heft 3, S. 307-339
ISSN: 0304-4130
Discussion of new forms of party organisation have largely focused on the ways in which institutionalised parties have adapted to pressures towards 'catch-all' or 'electoral-professional' behaviour. This article examines the ways in which new parties respond to these pressures. A model of the 'party as business firm' is generated from rational choice assumptions and it is suggested that such a model can emerge when new party systems are created in advanced societies. Two cases of political parties which resemble the business firm model in important ways are analysed in order to gauge the consequences of this type of party organisation: UCD in Spain and Forza Italia in Italy. On the basis of this analysis it is argued that business firm parties are likely to be electorally unstable and politically incoherent, and also prone to serving particularistic interests. (European Journal of Political Research / FUB)
World Affairs Online
In: Politics & society, Band 44, Heft 3, S. 345-371
ISSN: 0032-3292
Vitamin D is a hormone that acts on many genes expressed by immune cells. Evidence linking vitamin D deficiency with COVID-19 severity is circumstantial but considerable—links with ethnicity, obesity, institutionalization; latitude and ultraviolet exposure; increased lung damage in experimental models; associations with COVID-19 severity in hospitalized patients. Vitamin D deficiency is common but readily preventable by supplementation that is very safe and cheap. A target blood level of at least 50 nmol l−1, as indicated by the US National Academy of Medicine and by the European Food Safety Authority, is supported by evidence. This would require supplementation with 800 IU/day (not 400 IU/day as currently recommended in UK) to bring most people up to target. Randomized placebo-controlled trials of vitamin D in the community are unlikely to complete until spring 2021—although we note the positive results from Spain of a randomized trial of 25-hydroxyvitamin D3 (25(OH)D3 or calcifediol) in hospitalized patients. We urge UK and other governments to recommend vitamin D supplementation at 800–1000 IU/day for all, making it clear that this is to help optimize immune health and not solely for bone and muscle health. This should be mandated for prescription in care homes, prisons and other institutions where people are likely to have been indoors for much of the summer. Adults likely to be deficient should consider taking a higher dose, e.g. 4000 IU/day for the first four weeks before reducing to 800 IU–1000 IU/day. People admitted to the hospital with COVID-19 should have their vitamin D status checked and/or supplemented and consideration should be given to testing high-dose calcifediol in the RECOVERY trial. We feel this should be pursued with great urgency. Vitamin D levels in the UK will be falling from October onwards as we head into winter. There seems nothing to lose and potentially much to gain.
BASE